The MLL Leukemia
Although modern therapy for acute leukemia has improved greatly, there are genetic subsets of patients who respond very poorly to chemotherapy or relapse shortly post induction chemotherapy.
Leukemias with chromosome band 11q23 translocations are associated with early relapse, which involves the human Mixed Lineage Leukemia (MLL/HRX/ALL-1) gene. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] MLL translocations are found in at least 10% of de novo ALL and AML in children and adults. Of note, 80% of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) that arise in infants, and almost all cases of secondary AML that arise after treatment with topoisomerase II inhibitors are associated with MLL translocations. The leukemia blasts in infant ALL are usually CD19+, HLA-DR+, TdT+, CALLA-and cytoplasmic Ig-, consistent with an early precursor B-ALL. Furthermore, they also express the myelomonocytic marker, CD15. [13] [14] [15] The mixed phenotype of these blasts has led to a proposal that 11q23 abnormalities transform a multipotent stem cell or interrupt a differentiating cell.
Based on gene expression profiles, several groups had reported that ALL possessing a rearranged MLL exhibits a highly uniform and distinct pattern that clearly distinguishes them from conventional ALL or AML. [16] [17] [18] Their gene expression profiles are consistent with an early hematopoietic progenitor stage, expressing select multi-lineage markers and individual HOX genes. Studies using retrovirus-mediated gene transduction of MLL-Fusions in purified hematopoietic progenitors established that MLL leukemias can arise from hematopoietic stem cells (HSC), common myeloid progenitors (CMP), and granulocytic/monocytic-restricted progenitors (GMP), but not megakaryocytic/erythroid-restricted progenitors (MEP). [19] [20] [21] 
Fucntions of the MLL Gene
Located at the human chromosome band 11q23 breakpoints, MLL is the mammalian counterpart of Drosophila trithorax (Trx), the founder of trithorax group (Trx-G) genes. [22] [23] [24] [25] [26] [27] It is well characterized that trithorax group (Trx-G) proteins antagonize with polycomb group (Pc-G) proteins for proper Hox/homeotic gene expression through chromatin modifications. [28] [29] [30] As a transcription coactivator, MLL/Trx is required for the maintenance of spatial patterns of Hox and HOM-C (homeotic complex) genes in vertebrates and invertebrates, respectively. Homozygous deficiency for MLL results in early embryonic lethality at embryonic day 10.5 (E10.5), exhibiting multiple patterning defects, and heterozygous deletion of MLL incurs homeotic transformation, indicating altered Hox gene expression. [31] [32] [33] Recent studies also indicated an essential role of MLL in hematopoiesis. 34, 35 The MLL gene encodes a 3,969 amino acid, 500 kD protein consisting of multiple conserved domains with distinct biochemical properties (Fig. 1). (1) Three AT hooks, found near the N-terminus of MLL, mediate its binding to the minor groove of AT-rich DNA region. 36 (2) A transcription repression domain consists of a cysteinerich CXXC DNMT (DNA methyltransferase1) homology region. 37 (3) Four PHD fingers mediate protein-protein interactions. 38 (4) A transactivation (TA) domain interacts with p300/CBP. 39 (5) A C-terminal SET domain functions as a histone methyl transferase (HMT) that methylates Histone H3 at K4, marking transcriptionally active genes. 40, 41 Over the years, a plethora of MLL interaction partners have been identified, providing additional mechanistic insights regarding how MLL regulates complex gene expression. MLL complexes with Menin (a tumor suppressor), 42, 43 cell cycle regulators (E2Fs and HCF), [43] [44] [45] Pc-G proteins (Bmi-1 and HPC2), 37 HDACs (Histone Deacetylases), 41 Cyp33 (a nuclear cyclophilin), 37 CBP/P300 (Histone acetylase), 39 INI1/SNF5 (chromatin remodeling factors) 46 and core components of the H3K4 histone methyl transferase (WDR5 and Rbbp5). 47, 48 In addition to the aforementioned complexity of MLL gene regulation, we and others showed that the 500 kD full length MLL precursor (MLL FL ) undergoes evolutionarily conserved sitespecific proteolysis to generate a mature MLL N320/C180 heterodimer, consisting of the processed N-terminal 320 kD and C-terminal 180 kD fragments. 41, [49] [50] [51] 
Taspase1 Cleaves MLL: An Essential Step in MLL Activation
Proteolysis of MLL is an evolutionarily conserved process in that canonical cleavage sites (QV(L)D/GXXD) exist among all MLL orthologues from insects to vertebrates. 50 To understand the biological significance of MLL cleavage, we purified the responsible protease. 51 Biochemical purification of the MLL processing enzyme identified a previously uncharacterized orf13 (open reading frame) on human chromosome 20 (c20orf13). Detailed studies of c20orf13 confirmed that it encodes the bona fide protease mediating MLL proteolysis both in vitro and in vivo. 51 We named it Taspase1 (threonine aspartase 1) and the discovery of Taspase1 founded a new class of endopeptidases that utilize the N-terminal threonine of its mature β subunit as the active site nucleophile to cleave polypeptide substrates after an aspartate. 51 Taspase1 encodes a highly conserved 420 aa proenzyme which undergoes intramolecular proteolysis to produce an active α28/β22 heterodimer. 51 The Taspase1 heterodimer displays an overall α/β/β/α structure which further assembles into an asymmetric α2/β2 heterotetramer. 52 In addition to MLL family proteins, we also identified TFIIA family proteins, TFIIAα-β and ALF, and Drosophila HCF as novel Taspase1 substrates. 53, 54 We created Taspase1 deficient mice to investigate its participation in diverse signaling pathways. In the absence of Taspase1, MLL and its close homologue, MLL2, exist as uncleaved full length precursors. 44 Importantly, precursor MLL (MLL FL ) exhibits impaired HMT activity. 44 Consequently, Taspase1 -/-mice manifest with classical homeotic transformation resulted from deregulated Hox gene expression, in consistence with our proposed model 51 (Fig. 1 ). Our biochemical and genetic studies demonstrate that uncleaved MLL FL functions as a hypomorphic mutant. In other words, Taspase1-mediated proteolysis constitutes a post-translational program in activating precursor MLL. These observations provide the mechanistic basis explaining deficits associated with a hypomorphic Drosophila Trx allele (Trx E3 ), 55 which contains an in-frame deletion of the predicted Taspase1 cleavage site, thus generating a noncleavable Trx. Taken together, Taspase1-mediated cleavage of MLL/Trx is an evolutionarily conserved regulatory event that ensures a correct spatial and temporal activation of MLL/Trx downstream targets.
Homozygous disruption of MLL in mice results in early embryonic lethality and heterozygous deficiency results in homeotic transformation due to impaired maintenance of Hox genes. 31 The early lethality of MLL -/-mouse embryos precludes detailed investigation of its involvement in other signalling pathways. Although the underlying mechanisms were not further investigated, initial characterizations on MLL -/-mice suggest a role of MLL in proliferation in addition to differentiation. For example, MLL -/-fetal liver or yolk sac hematopoietic cells grow slower and form smaller colonies in methyl cellulose assays. 32, 56 Our demonstration that MLL is regulated by Taspase1-mediated proteolytic cleavage broadens the avenue in studying MLL in that non-cleaved precursor MLL functions as a hypomorphic mutant. 44 In addition to the predicted homeotic transformation resulted from altered Hox gene expression, our studies on Taspase1 -/-animals uncovered an essential role of Taspase1 in orchestrating cell cycle progression-Taspase1 deficiency causes defects in cell cycle regulation. 44 Mechanistic studies revealed deregulated expression of key cell cycle regulators, including downregulation of Cyclin E, A, B and upregulations of p16 Ink4a and ARF. MLL and MLL2 are critical substrates in Taspase1-mediated cell cycle control, which was confirmed by the proliferation defects in MLL nc/nc;2nc/nc MEFs (cells carry double homozygous noncleavable (nc) knockin alleles of MLL and MLL2). MLLs interact with E2Fs, core transcription factors of the cell cycle, to modulate expression of Cyclins. MLL proteolysis by Taspase1 is required to generate a fully functional mature MLL N320/ C180 heterodimer. The uncleaved full length precursor MLL FL is inefficient in histone H3 methylation both in vivo and in vitro. 44 Taken together, full length precursor MLL FL s, following cleavage by Taspase1, target to Cyclins through their interactions with E2Fs to methylate histone H3 at K4, thus activating cell cycle regulatory genes. 44 
The Intricate Interplay Between MLL and Cell Cycle Machinery
Eukaryotic cell cycle consists of a tightly orchestrated circular progression of a sequence of distinct phases-namely G 1 , S, G 2 and M-designated for the execution of inherent genetic programs. 57 Key regulatory components of the mammalian cell cycle machinery include E2Fs, Rbs, Cyclins, Cyclin dependent kinases (CDKs), and CDK inhibitors (CDKIs), which form complex positive and negative epistatic circuits to ensure accurate cell cycle progression. 58 The molecular blueprint of a normal cell cycle details the central controls held by a series of CDKs which positively influence proliferation through phosphorylatioin of target proteins such as Rbs. 59 This releases the repressive activities of Rbs on E2Fs-executors of the cell cycle genetic program. [60] [61] [62] [63] [64] Individual CDKs need to complex with specialized Cyclins to form catalytically active CDK/Cyclins. Therefore, their activities depend on the availability of involved Cyclins. Additional regulation of CDK/Cyclins comes from negative factors, the CDKIs. 65 Levels of Cyclins and CDKIs undulate during the cell division cycle, which in part is due to defined windows of degradation by the ubiquitin-proteasome system (UPS). 66 UPS commences at substrate recognition and the subsequent covalent conjugation of ubiquitin by responsible E3 ligases, followed by degradation executed by the 26S proteasome. 67 The two major E3 complexes involved in proteolyzing core components of the cell cycle machinery are SCF (Skp1-Cul1-F-box protein) and APC (anaphase-promoting complex/cyclosome) complexes, of which the substrate recognition is conducted by the variable components-F box proteins for SCF, and Cdc20 or Cdh1 for APC. [68] [69] [70] Thus, two types of post-translational modifications-phosphorylation and ubiquitination-constitute the two main controls of cell cycle.
Our studies on cells deficient for Taspase1 or bearing non-cleavable alleles of MLL, MLL nc/nc , recognize the participation of MLL through E2Fs in regulating cell proliferation, linking MLL proteolysis to the heart of cell cycle gene programming. 44 The essential role of MLL in cell cycle progression through the MLL-E2F axis is further supported by a recent report indicating that HCF-1, MLL and E2F form tertiary complex on E2F-responsive promoters during the G 1 /S phase transition, thereby inducing histone methylation and transcriptional activation. 45 The active involvement of MLL/Trx in the cell cycle is conserved through evolution in that genetic studies in Drosophila also highlight a critical role of Trx in cell proliferation. 71 Additionally, several recent reports also identified MLL as a direct activator of Cyclins and CDKIs. 44, 45, 72, 73 To further investigate how MLL regulates the cell cycle, we examined protein level of MLL through the cell cycle and observed a tightly controlled biphasic expression of MLL in all cell types. 74 This unique expression is conferred by defined windows of degradation mediated by specialized cell cycle E3 ligases, SCF Skp2 and APC Cdc20 (Fig. 1) . 74 Importantly, two peak expressions of MLL ensure corresponding G 1 /S transition and M phase progression. Disruption of this unique expression pattern by shRNA-mediated knockdown of MLL causes defects in G 1 /S entry and M phase progression. 74 Furthermore, overexpression of MLL incurs specific S phase defects, indicating the importance of downregulating its activity in the S phase. However, whether this is resulted from sustained expression of downstream key cell cycle regulators, and/or overexpressed MLL invoked yet identified insults remains to be determined.
These data not only highlight the significance of biphasic MLL expression in orchestrating cell division cycle but also uncover a novel mechanism by which the cell cycle machinery regulates MLL. 74 This establishes another irreversible post-translational regulation of MLL through degradation in addition to Taspase1-mediated site-specific proteolysis. As MLL directly activates transcription of Cyclins that exhibit periodic expression during cell proliferation, it is imperative for a cell to incorporate MLL expression into the intricately assembled cell cycle circuitry, ensuring a correct transition of progressive phases.
It seems counterintuitive at the first glance that MLL/Trx activates both Cyclins 44, 45 and CDKIs, 72, 73 positive and negative regulators of the cell cycle, respectively. It is plausible that MLL/Trx targets downstream genes in a cell cycle phase-dependent manner. Indeed, a cell cycle specific recruitment of MLL/Trx to its target genes such as CyclinA has been reported. 45 Biphasic expression of MLL assures target genes to be activated and inactivated following a tightly choreographed temporal sequence. Based on available reports, we propose the following model detailing how MLL coordinates the G 1 /S transition (Fig. 2) . 44, 45, [73] [74] [75] [76] In the mid-G 1 phase, the rising MLL level activates both p27 and CyclinE that assemble into an inactive CDK2/CyclinE/p27 complex which prepares the cell for G 1 /S entry. In the late G 1 phase, MLL further activates CyclinE leading to an excess of active CDK2/CyclinE complex that marks p27 for degradation through phosphorylation. Downregulated p27 along with the concurrent increase of CyclinE eventually marshals cells through the G 1 /S transition. Once entering the G 1 /S transition, MLL is recruited to the promoter of CyclinA. 45 Increased CyclinA replaces CyclinE, thereby facilitating the assembly of CDK2/CyclinA complex for S phase progression. Upon a successful entry into the S phase, MLL is no longer needed and thus degraded by the SCF Skp2 E3 ligase (Fig.  2) .
Models of the MLL Leukemia
Human chromosome 11q23 aberrations disrupting MLL lead to infant and therapy-related leukemias. These balanced translocations fuse the N-terminal ~1400 aa of MLL in-frame with a wide spectrum of fusion partners, generating pathognomonic leukemogenic MLL-Fusions. Mysteriously, among these (>50) fusion partners, no shared characteristics were recognized based on sequence or structure homology. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Genetic studies on mice carrying individual MLL-Fusions reveal several fundamental aspects concerning the MLL leukemia. First, MLL-Fusions from 11q23 translocations are responsible for the leukemogenesis. [77] [78] [79] [80] [81] Second, fusion partners are indispensable. 82 Third, partners can be as non-specific as bacterial galactosidase (LacZ) in that mice bearing MLL-LacZ developed myeloid leukemias after a prolonged latency. 82 Fourth, individual partners determine the phenotypes of resulting leukemias. For example, mice carrying MLL-AF4 or MLL-AF9 develop lymphoid versus myeloid malignancies, mimicking their respective human counterparts. 78, 80, 83 Detailed analyses of individual MLL-Fusions using retrovirus-mediated gene transduction of hematopoietic stem/ progenitor cells provide insightful mechanistic explanations regarding the MLL leukemia. [84] [85] [86] [87] [88] [89] These studies established important models such as transactivation and dimerization-emphasizing the gain of Hox gene expression, thus interfering blood lineage commitment (Fig. 3) . 85, [90] [91] [92] However, these two models are only suitable for subsets of MLL leukemias since not all fusion partners contain transactivation or dimerization domains.
As mice bearing MLL-LacZ developed leukemias, it has been postulated that LacZ induces leukemias through either oligomerizing or stabilizing the MLL N-terminus-two non-mutually exclusive mechanisms. 82 Although stabilization may contribute to MLL leukemogenesis, it has not been further examined. Our initial studies on the site-specific proteolysis of MLL indicated that proteolytic cleavages of MLL not only regulates its activation but also stability. 50 Based on our prior studies on the unstable nature of MLL N-terminus, we had proposed a model in which fusion partners stabilize the common MLL N-terminus for downstream gene regulation-a mechanism compatible with the prevailing activation and dimerization models. 50 In a recent report, we further investigated this mechanism and discovered that degradation of MLL initiates at its N-terminal ~1400 aa that is universally retained in all documented MLL leukemia fusions. 74 Importantly, the prevalent MLL-Fusions, including MLL-AF4, MLL-AF9, MLL-ENL and MLL-ELL, and leukemogenic MLL-LacZ all exhibit resistance to degradation mediated by respective cell cycle UPS. This is in part due to the diminished interaction between N-terminal MLL and Skp2 or Cdc20, which results in an uncontrolled constant presence of MLLFusions through the cell cycle. 74 As activation and dimerization models are only applicable to certain MLL-Fusions, a unifying model could exist to explain the wide variety of fusion partners. As MLL-LacZ is resistant to cell cycle phase-specific degradation, it is possible that partner proteins with oligomerizing capacity stabilize the respective MLL-Fusions (Fig. 3) . Consequently, MLL target genes become constantly activated due to unmonitored expression of MLL-Fusions. Our studies uncovered a functional commonality among structurally diversified fusion partners, which yields a model in which partners interfere with the recognition of respective MLL-Fusions by cell cycle E3 ligases, resulting in their non-oscillating expression (Fig. 3) . Importantly, our stabilization model is mechanistically compatible with and likely constitutes the basis underlying established transactivation and dimerization models, explaining the myriad fusion partners with no structural analogy (Fig. 3) .
The Contributions of Cell Cycle Deregulation to MLL Leukemias
HOX gene clusters encode highly conserved transcription factors with critical roles in embryonic development and hematopoiesis. 93, 94 As HOX genes are the best characterized MLL targets, significance of their deregulation in MLL leukemias has been extensively studied. [95] [96] [97] [98] Hox deregulation is required for certain but not all MLL-Fusions induced leukemias. For instance, HoxA7 and HoxA9 are prerequisite for MLL-ENL initiated leukemia 95 but are dispensable for leukemias induced by MLL-AF9 and MLL-GAS7. 96, 97 Therefore, it is likely that deregulation of critical pathways other than Hox genes plays an instrumental role in MLL leukemias. A few reports including ours have begun to explore the roles of MLL/MLL-Fusions in cell cycle, genome integrity, etc.,-an uncharted area demanding further efforts. 44, [71] [72] [73] [74] 99, 100 Initial emphasis on Hox gene deregulation provides an important yet oversimplified view concerning the MLL leukemia. Hence, future elucidation and validation of additional signaling pathways controlled by MLL and their respective deregulation incurred by MLL-Fusions would likely yield novel targets for future treatment of the MLL leukemia.
Our observed cell cycle defects from perturbations of MLL expression led to hypothesize that MLL-Fusions interfere with the cell cycle, which is supported by prior overexpression studies using either MLL-AF4 or MLL-AF9. 71, 72 The resistance of MLL-Fusion to cell cycle phase-specific degradation results in its non-oscillating expression during the cell division cycle. 74 Although the consequences of such deregulated expression remain to be determined, the loss of temporal control of MLL targets likely contributes to the ultimate MLL leukemia phenotype. 71, 72, 101 The Trx-G and Pc-G in Oncogenesis Genetic evidences obtained from studying flies and mammals establish the fundamental roles of Pc-G and Trx-G proteins in maintaining Hox/homeotic gene expression, thus ensuring the correct instalment of complex segmental body plans in higher organisms. Recent studies revealed an even more perplexed relationship between these two groups of proteins in regulating non-Hox/homeotic pathways. For example, they target similar cell cycle genes such as CyclinA and p16. 44, 102, 103 Furthermore, deregulation of factors belonging to either groups affects hematopoiesis and contributes to various oncogenic processes. 34, 35, 104, 105 Bmi-1, a Pc-G protein, is well recognized for its ability to accelerate Myc-induced lymphoma in mice. 103 Subsequent studies on Bmi-1-associated oncogenesis primarily emphasize on the ability of Bmi-1 to suppress the expression of tumour suppressors, p16 Ink4a and ARF, thus promoting caner cell proliferation. 106 Surprisingly, despite its well established role in Hox gene regulation, the significance of Bmi-1-induced Hox gene alterations in Bmi-1-mediated oncogenesis remains undetermined. On the contrary, studies on MLL, the founder of Trx-G proteins, and its associated leukemias clearly recognize the potential mechanistic importance of overexpression of Hox genes in leukemogenesis. Similarly, whether aberrant cell cycle gene expression contributes to MLL leukemogenesis remains undetermined. Based on our findings linking MLL/MLL Fusions to the cell cycle regulation, we propose that a simultaneous deregulation of differentiation and proliferation through Hox and cell cycle genes by Bmi-1 and MLL is of paramount importance in respective carcinogenesis (Fig. 4) .
Conclusions and Future Directions
Although our recent studies elucidated the intimate relationship between MLL and the cell cycle control, 44, 74 the in vivo consequences incurred by non-oscillating expression of MLL-Fusions remain to be elucidated. Studies by us and others clearly indicate the importance to avoid expressing MLL/MLL-Fusions at a nonphysiological level-expression of MLL/MLL-Fusions beyond or below the physiological range incurs undesirable cell cycle consequences that may easily lead to an erroneous conclusion. Therefore, to critically examine cell cycle defects associated with MLL-Fusions, one has to employ cells bearing knockin allele of MLL-Fusion of which its expression is directly controlled by the endogenous MLL promoter.
The most characterized biochemical property of MLL is its activity to methylate Histone H3 at K4 position with its C-terminal SET domain, thus marking the active epigenome. However, this highly conserved SET domain only represents less than 5% of MLL which is made of 3,969 amino acid residues. Furthermore, the ubiquitous expression of MLL implicates its participation in essential cellular processes other than cell fate decisions. Recent positioning of MLL in the cell division cycle inaugurated the search for noncanonical functions of MLL. Although it has been a decade since its debut, there are treasures ahead awaiting future discoverers. Hence, we anticipate to witnessing exciting discoveries of unrecognized critical functions of the multi-talented MLL protein by scientists from various disciplines. Figure 4 . A diagram highlights the intricate relationship and draws the analogy between MLL, a Trx-G protein and Bmi-1, a Pc-G protein, in embryogenesis and oncogenesis.
